What is Disc Medicine's payments of debt issuance costs?

Disc Medicine (IRON) reported payments of debt issuance costs of $0 in Q4 2025.

How has Disc Medicine's payments of debt issuance costs changed year-over-year?

Disc Medicine's payments of debt issuance costs decreased by 100.0% year-over-year, from $348.25K to $0.

Beam TherapeuticsBEAM

——

Operating income-$69.5M-74.0%

Net income-$63.5M-86.3%

EPS (diluted)-$1.65-61.8%

Cash & equivalents$88.9M-27.5%

Total debt$31.1M+1.4%

Total equity$688.4M+4.3%

Total assets$750.2M+5.8%

Operating cash flow-$62.2M-50.4%

CapEx--100%

Free cash flow-$62.2M-47.4%

Market cap$2.69B+42.2%

Enterprise value$2.63B+46.7%

Return on equity-35.8%+41.3pp

Debt / equity0×0.0×

Current ratio24×-13.6×

Reported directly by Disc Medicine in its filing.

Tagged under the XBRL concept us-gaap:PaymentsOfDebtIssuanceCosts.

The official record: Disc Medicine’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Disc Medicine's payments of debt issuance costs?: Disc Medicine (IRON) reported payments of debt issuance costs of $0 in Q4 2025.
How has Disc Medicine's payments of debt issuance costs changed year-over-year?: Disc Medicine's payments of debt issuance costs decreased by 100.0% year-over-year, from $348.25K to $0.